LIVIVO - Search results -

Search results

Result 1 - 10 of total 98

Search options

Article ; Online: Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.

Jean, Shio-Shin / Harnod, Dorji / Hsueh, Po-Ren

Frontiers in cellular and infection microbiology

2022 Volume 12, Page(s) 823684

Abstract: Infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; harboring ... ...

Abstract	Infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; harboring mainly
MeSH term(s)	Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Carbapenems/pharmacology ; Carbapenems/therapeutic use ; Drug Resistance, Multiple, Bacterial ; Gram-Negative Bacteria/genetics ; Microbial Sensitivity Tests
Chemical Substances	Anti-Bacterial Agents ; Carbapenems
Language	English
Publishing date	2022-03-15
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2619676-1
ISSN	2235-2988 ; 2235-2988
ISSN (online)	2235-2988
ISSN	2235-2988
DOI	10.3389/fcimb.2022.823684
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Old and re-purposed drugs for the treatment of COVID-19.

Jean, Shio-Shin / Hsueh, Po-Ren

Expert review of anti-infective therapy

2020 Volume 18, Issue 9, Page(s) 843–847

Abstract: ... ...

Abstract	Introduction
MeSH term(s)	Angiotensin Receptor Antagonists/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Antiviral Agents/pharmacology ; Betacoronavirus/drug effects ; COVID-19 ; Coronavirus Infections/drug therapy ; Drug Repositioning/methods ; Humans ; Immunologic Factors/pharmacology ; Pandemics ; Pneumonia, Viral/drug therapy ; SARS-CoV-2 ; Treatment Outcome
Chemical Substances	Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Antiviral Agents ; Immunologic Factors
Keywords	covid19
Language	English
Publishing date	2020-06-01
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2181279-2
ISSN	1744-8336 ; 1478-7210
ISSN (online)	1744-8336
ISSN	1478-7210
DOI	10.1080/14787210.2020.1771181
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6106: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Use of Multiple Doses of Intravenous Infusion of Umbilical Cord-Mesenchymal Stem Cells for the Treatment of Adult Patients with Severe COVID-19-Related Acute Respiratory Distress Syndrome: Literature Review.

Hsueh, Po-Ren / Ho, Sung-Jung / Hsieh, Po-Chuen / Liu, I-Min / Jean, Shio-Shin

Stem cells international

2023 Volume 2023, Page(s) 7179592

Abstract: Objectives: Acute respiratory distress syndrome (ARDS) is a critical complication in severe COVID-19 patients. The intravenous infusion (IVF) of umbilical cord- (UC-) mesenchymal stem cells (MSCs), validated to substantially reduce the release of ... ...

Abstract	Objectives: Acute respiratory distress syndrome (ARDS) is a critical complication in severe COVID-19 patients. The intravenous infusion (IVF) of umbilical cord- (UC-) mesenchymal stem cells (MSCs), validated to substantially reduce the release of several inflammatory cytokines Methods: We reviewed the 2020-2022 PubMed literature database concerning the clinical efficacy of IVF-UC-MSCs among severe COVID-19 patients. Results: The data of COVID-19 case series in the PubMed literature revealed a notable heterogeneity in the therapeutic dosage (a single dose: 1-10 × 10 Conclusions: According to our analysis, the ideal treatment dosage of IVF-UC-MSCs for severe COVID-19-induced ARDS is likely 5 × 10
Language	English
Publishing date	2023-08-18
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2573856-2
ISSN	1687-9678 ; 1687-966X
ISSN (online)	1687-9678
ISSN	1687-966X
DOI	10.1155/2023/7179592
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Minimum inhibitory concentrations of antifungals against invasive isolates of Cryptococcus species worldwide: Global antifungal antimicrobial testing leadership and surveillance program, 2010-2020.

Jean, Shio-Shin / Liu, Chia-Ying / Huang, Yu-Tsung / Ko, Wen-Chien / Ho, Mao-Wang / Liu, I-Min / Hsieh, Po-Chuen / Hsueh, Po-Ren

International journal of antimicrobial agents

2024 Volume 63, Issue 3, Page(s) 107090

Abstract: This study examined the geographic distribution of minimum inhibitory concentrations (MICs) of antifungals against Cryptococcus isolates. Data were collected on the MICs of specific antifungals (amphotericin B, 5-flucytosine, fluconazole, voriconazole, ... ...

Abstract	This study examined the geographic distribution of minimum inhibitory concentrations (MICs) of antifungals against Cryptococcus isolates. Data were collected on the MICs of specific antifungals (amphotericin B, 5-flucytosine, fluconazole, voriconazole, posaconazole, and isavuconazole) against various Cryptococcus species for the period 2010 to 2020 from the Antimicrobial Testing Leadership and Surveillance database. Cryptococcus isolates were collected from samples of blood and cerebrospinal fluid (CSF) from patients hospitalized in different regions worldwide. We applied the epidemiological cutoff values (ECVs) of antifungals against various Cryptococcus species to distinguish wild-type (WT) from non-WT Cryptococcus isolates. A total of 395 isolates of Cryptococcus species cultured from blood (n = 201) or CSF (n = 194) were analyzed. C. grubii (n = 270), C. neoformans (n = 111), and C. gattii (n = 11) were the three predominant species causing bloodstream infections (BSI) or meningitis/meningoencephalitis (MME). The proportion of MICs above the ECV (1 mg/L) for amphotericin B among C. neoformans isolates was significantly lower than that among C. gattii isolates (MICs >0.5 mg/L; P < 0.001), as evaluated using the chi-square test. For most isolates of the three predominant Cryptococcus species, the MICs of new triazoles were ≤0.25 mg/L. The MICs of fluconazole and amphotericin B in the BSI/MME-causing Cryptococcus isolates collected from patients hospitalized in the Asia-Western Pacific region and Europe were significantly lower (i.e., the distributions were more leftward) than those in North America and Latin America. Ongoing monitoring of MIC data for important antifungals against cryptococcosis is crucial.
MeSH term(s)	Humans ; Antifungal Agents/pharmacology ; Amphotericin B ; Fluconazole/pharmacology ; Leadership ; Anti-Infective Agents ; Cryptococcus neoformans ; Cryptococcus gattii ; Endrin/analogs & derivatives
Chemical Substances	Antifungal Agents ; Amphotericin B (7XU7A7DROE) ; Fluconazole (8VZV102JFY) ; MME (78185-58-7) ; Anti-Infective Agents ; Endrin (OB9NVE7YCL)
Language	English
Publishing date	2024-01-18
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2024.107090
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014-2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment.

Hsueh, Shun-Chung / Huang, Yu-Tsung / Ko, Wen-Chien / Liu, I-Min / Hsieh, Po-Chuen / Jean, Shio-Shin

Journal of global antimicrobial resistance

2024 Volume 36, Page(s) 411–418

Abstract: Objectives: To evaluate the susceptibility of globally pneumonia-causing meropenem-resistant (MEM-R) Acinetobacter baumannii isolates against important antibiotics and estimate appropriate dosages of indicated antibiotics.: Methods: We extracted the ... ...

Abstract	Objectives: To evaluate the susceptibility of globally pneumonia-causing meropenem-resistant (MEM-R) Acinetobacter baumannii isolates against important antibiotics and estimate appropriate dosages of indicated antibiotics. Methods: We extracted the 2014-2021 Antimicrobial Testing of Leadership Surveillance database regarding the susceptibility of MEM-R A. baumannii isolates causing pneumonia against important antibiotics. The susceptibility and carbapenemase-encoding gene (CPEG) data of pneumonia-causing MEM-R A. baumannii isolates from patients hospitalized in intensive care units of five major regions were analyzed. The susceptibility breakpoints (SBP) recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2022, other necessary criteria [SBP of MIC for colistin, 2 mg/L, in the CLSI 2018; and cefoperazone-sulbactam (CFP-SUL), 16 mg/L], and the pharmacokinetic and pharmacodynamic data of indicated antibiotics were employed. Results: Applying the aforementioned criteria, we observed the susceptible rates of colistin, minocycline, and CFP-SUL against the pneumonia-causing MEM-R A. baumannii isolates globally (n = 2905) were 93.2%, 69.1%, and 26.3%, respectively. Minocycline was significantly more active in vitro (MIC ≤4 mg/L) against the pneumonia-causing MEM-R A. baumannii isolates collected from North and South America compared to those from other regions (>90% vs. 58-72%). Additionally, bla Conclusions: After deliberative estimations, dosages of 200 mg minocycline intravenously every 12 h (SBP, 8 mg/L), 100 mg tigecycline intravenously every 12 h (SBP, 1 mg/L), and 160 mg nebulized colistin methanesulphonate every 8 h (SBP, 2 mg/L) are needed for the effective treatment of pneumonia-causing MEM-R A. baumannii isolates.
MeSH term(s)	Humans ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Meropenem/pharmacology ; Meropenem/therapeutic use ; Minocycline/pharmacology ; Acinetobacter baumannii ; Colistin/pharmacology ; Colistin/therapeutic use ; Leadership ; Drug Resistance, Multiple, Bacterial ; Acinetobacter Infections/drug therapy ; Anti-Infective Agents/pharmacology ; Pneumonia/drug therapy
Chemical Substances	Anti-Bacterial Agents ; Meropenem (FV9J3JU8B1) ; Minocycline (FYY3R43WGO) ; Colistin (Z67X93HJG1) ; Anti-Infective Agents
Language	English
Publishing date	2024-02-06
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2710046-7
ISSN	2213-7173 ; 2213-7173
ISSN (online)	2213-7173
ISSN	2213-7173
DOI	10.1016/j.jgar.2024.01.019
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-β-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership and Surveillance Programme, 2012-2019.

Jean, Shio-Shin / Lee, Yu-Lin / Hsu, Chin-Wang / Hsueh, Po-Ren

International journal of antimicrobial agents

2022 Volume 60, Issue 3, Page(s) 106617

Abstract: Objectives: A total of 74 570 potentially naturally inducible chromosomal AmpC-producing (PNIC-AmpC) Enterobacterales isolates included in the Antimicrobial Testing Leadership and Surveillance Programme were obtained worldwide during 2012-2019 (22 503 ... ...

Abstract	Objectives: A total of 74 570 potentially naturally inducible chromosomal AmpC-producing (PNIC-AmpC) Enterobacterales isolates included in the Antimicrobial Testing Leadership and Surveillance Programme were obtained worldwide during 2012-2019 (22 503 from 2012-2014 and 52 067 from 2015-2019). Of these isolates, 117 and 711 obtained during 2012-2014 and 2015-2019, respectively, were carbapenem-resistant Enterobacterales (PNIC-AmpC-CRE). The MICs of ceftazidime-avibactam for these isolates were determined using the broth microdilution method. Methods: Genes encoding different Ambler classes of β-lactamases were investigated using multiplex PCR. After 97 isolates harbouring genes encoding metallo-β-lactamases (MβL) were excluded, 731 PNIC-AmpC MβL-negative CRE isolates (101 from 2012-2014 and 630 from 2015-2019) were included in this study. Results: Enterobacter cloacae (E. cloacae) complex species, Escherichia coli (E. coli) and Citrobacter freundii (C. freundii) complex species accounted for 36.3% (n = 265), 30.4% (n = 222) and 11.8% (n = 86), respectively, followed by Providencia species (n = 72), Serratia species (n = 52) and Klebsiella aerogenes (n = 34). The resistance rates to ceftazidime-avibactam for the overall PNIC-AmpC MβL-negative CRE isolates markedly differed between the two periods (35.6% vs. 63.3%; P < 0.001). Similar trends were observed for the MβL-negative-CR-E. cloacae complex species (47.4% vs. 65.2%; P = 0.046) and MβL-negative-CR-E. coli (16.2% vs. 63.8%; P < 0.001) but not for MβL-negative-CR-C. freundii complex species (40% vs. 62%; P = 0.153). Amongst the PNIC-AmpC MβL-negative CRE isolates, resistance rates to ceftazidime-avibactam worsened. Conclusions: Caution should be taken when empirically prescribing ceftazidime-avibactam for infections caused by PNIC-AmpC-CRE before susceptibility data are available.
MeSH term(s)	Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/pharmacology ; Carbapenems/pharmacology ; Ceftazidime/pharmacology ; Drug Combinations ; Escherichia coli ; Leadership ; Microbial Sensitivity Tests ; beta-Lactamases/genetics
Chemical Substances	Anti-Bacterial Agents ; Azabicyclo Compounds ; Carbapenems ; Drug Combinations ; avibactam, ceftazidime drug combination ; Ceftazidime (9M416Z9QNR) ; beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2022-06-17
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2022.106617
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Old and re-purposed drugs for the treatment of COVID-19

Jean, Shio-Shin / Hsueh, Po-Ren

Expert Review of Anti-infective Therapy

2020 Volume 18, Issue 9, Page(s) 843–847

Keywords	Microbiology (medical) ; Microbiology ; Virology ; Infectious Diseases ; covid19
Language	English
Publisher	Informa UK Limited
Publishing country	uk
Document type	Article ; Online
ZDB-ID	2181279-2
ISSN	1744-8336 ; 1478-7210
ISSN (online)	1744-8336
ISSN	1478-7210
DOI	10.1080/14787210.2020.1771181
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 6106: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Antimicrobial susceptibilities of the ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales isolates causing intra-abdominal infections in the Asia-Pacific region during 2008-2014: Results from the Study for Monitoring the Antimicrobial Resistance Trends (SMART).

Jean, Shio-Shin / Hsueh, Po-Ren

Journal of global antimicrobial resistance

2019 Volume 21, Page(s) 91–98

Abstract: Objectives: To investigate the susceptibility profiles amongst ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales (ETP-NS-non-CPE) isolates.: Methods: Minimum inhibitory concentrations (MICs) of 404 ETP-NS-non-CPE isolates ... ...

Abstract	Objectives: To investigate the susceptibility profiles amongst ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales (ETP-NS-non-CPE) isolates. Methods: Minimum inhibitory concentrations (MICs) of 404 ETP-NS-non-CPE isolates collected from different intra-abdominal infection (IAI) sites amongst patients in the Asia-Pacific region during 2008-2014 were determined using the broth microdilution method. The susceptibility results were interpreted according to the MIC breakpoints recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2018. The MICs data of several agents were evaluated based on their published pharmacokinetic/pharmacodynamic (PK/PD) profiles. Results: The majority (>84%) of IAI-ETP-NS-non-CPE isolates - including Escherichia coli (n=83), Klebsiella pneumoniae (n=91) and Enterobacter species (n=210) - were susceptible to imipenem and amikacin. The 193 hepatobiliary ETP-NS-non-CPE isolates exhibited a trend of lower cefepime MIC (≤4mg/L) distribution than those (n=145) cultured from the peritoneal space (P=0.058). Amongst the ETP-NS-non-CP Enterobacter isolates, 65.7% displayed a cefepime MIC≤4mg/L. In addition, compared with Escherichia coli and Klebsiella pneumoniae isolates, 82.9% and 72.9% of the ETP-NS-non-CP Enterobacter isolates were susceptible to levofloxacin and ciprofloxacin, respectively. Of note, 74.5% and 70.3% of the ETP-NS-non-CP Enterobacter isolates cultured from the hepatobiliary tract and peritoneal space exhibited a ciprofloxacin MIC≤2mg/L and ≤0.25mg/L, respectively. Imipenem and amikacin showed good in vitro susceptibility rates against the IAI-ETP-NS-non-CPE isolates. The hepatobiliary ETP-NS-non-CPE displayed lower cefepime MICs than those cultured from the peritoneal space. Additionally, a significant fraction of IAI-ETP-NS-non-CP Enterobacter isolates exhibited ciprofloxacin MIC ≤ 2mg/L. Conclusion: Based upon the PK/PD analyses, ciprofloxacin, imipenem and cefepime are probably effective against IAI-ETP-NS-non-CPE isolates.
MeSH term(s)	Amikacin/pharmacokinetics ; Amikacin/pharmacology ; Asia ; Ciprofloxacin/pharmacokinetics ; Ciprofloxacin/pharmacology ; Drug Resistance, Bacterial ; Enterobacter/drug effects ; Enterobacter/isolation & purification ; Enterobacteriaceae/classification ; Enterobacteriaceae/drug effects ; Enterobacteriaceae/isolation & purification ; Enterobacteriaceae Infections/diagnosis ; Ertapenem/pharmacology ; Escherichia coli/drug effects ; Escherichia coli/isolation & purification ; Humans ; Imipenem/pharmacokinetics ; Imipenem/pharmacology ; Intraabdominal Infections/microbiology ; Klebsiella pneumoniae/drug effects ; Klebsiella pneumoniae/isolation & purification ; Microbial Sensitivity Tests ; Pacific Islands ; Population Surveillance
Chemical Substances	Ciprofloxacin (5E8K9I0O4U) ; Imipenem (71OTZ9ZE0A) ; Amikacin (84319SGC3C) ; Ertapenem (G32F6EID2H)
Language	English
Publishing date	2019-10-15
Publishing country	Netherlands
Document type	Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2710046-7
ISSN	2213-7173 ; 2213-7165
ISSN (online)	2213-7173
ISSN	2213-7165
DOI	10.1016/j.jgar.2019.10.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Multicenter surveillance of

Jean, Shio-Shin / Ko, Wen-Chien / Lu, Min-Chi / Lee, Wen-Sen / Hsueh, Po-Ren

Expert review of anti-infective therapy

2022 Volume 20, Issue 6, Page(s) 941–953

Abstract: Objectives: To determine the : Methods: Isolates of : Results: The MIC values of the cefepime-enmetazobactam combination against extended-spectrum β-lactamase-producing : Conclusions: The efficacy of novel antibiotics against important drug- ... ...

Abstract	Objectives: To determine the Methods: Isolates of Results: The MIC values of the cefepime-enmetazobactam combination against extended-spectrum β-lactamase-producing Conclusions: The efficacy of novel antibiotics against important drug-resistant GNB must be monitored and validated during the clinical treatment of patients.
MeSH term(s)	Acinetobacter baumannii/genetics ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/pharmacology ; Carbapenems ; Cefepime/pharmacology ; Cephalosporins/pharmacology ; Cyclooctanes ; Escherichia coli ; Humans ; Microbial Sensitivity Tests ; Pseudomonas aeruginosa/genetics ; Sepsis/drug therapy ; Taiwan ; Tetracyclines ; Triazoles ; beta-Lactamases/genetics
Chemical Substances	Anti-Bacterial Agents ; Azabicyclo Compounds ; Carbapenems ; Cephalosporins ; Cyclooctanes ; Tetracyclines ; Triazoles ; WCK 5222 ; eravacycline (07896928ZC) ; omadacycline (090IP5RV8F) ; Cefepime (807PW4VQE3) ; enmetazobactam (80VUN7L00C) ; beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2022-01-11
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2181279-2
ISSN	1744-8336 ; 1478-7210
ISSN (online)	1744-8336
ISSN	1478-7210
DOI	10.1080/14787210.2022.2021876
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6106: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-β-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership and Surveillance Programme, 2012–2019

Jean, Shio-Shin / Lee, Yu-Lin / Hsu, Chin-Wang / Hsueh, Po-Ren

International journal of antimicrobial agents. 2022 June 12,

2022

Abstract: In total, 74,570 potentially naturally inducible chromosomal AmpC-producing (PNIC-AmpC) Enterobacterales isolates included in the Antimicrobial Testing Leadership and Surveillance Programme were obtained worldwide from 2012 to 2019 (22,503 from 2012 to ... ...

Abstract	In total, 74,570 potentially naturally inducible chromosomal AmpC-producing (PNIC-AmpC) Enterobacterales isolates included in the Antimicrobial Testing Leadership and Surveillance Programme were obtained worldwide from 2012 to 2019 (22,503 from 2012 to 2014 and 52,067 from 2015 to 2019). One hundred seventeen and 711 isolates obtained in 2012–2014 and 2015–2019, respectively, were carbapenem-resistant Enterobacterales (PNIC-AmpC-CRE). The minimum inhibitory concentrations of ceftazidime-avibactam for these isolates against were determined using the broth microdilution method. Genes encoding different Ambler classes of β-lactamases were investigated using multiplex PCR. After 97 isolates harboring genes encoding metallo-β-lactamases (MβL) were excluded, 731 PNIC-AmpC MβL-negative CRE isolates (101 from 2012 to 2014 and 630 from 2015 to 2019) were included in this study. Enterobacter cloacae complex species, Escherichia coli, and Citrobacter freundii complex species accounted for 36.3% (n = 265), 30.4% (n = 222), and 11.8% (n = 86), respectively, followed by Providencia species (n = 72), Serratia species (n = 52), and Klebsiella aerogenes (n = 34). The resistance rates to ceftazidime-avibactam for the overall PNIC-AmpC MβL-negative CRE isolates differed markedly between the two periods (35.6% vs. 63.3%, P < 0.001). Similar trends were observed for the MβL-negative-CR-E. cloacae complex species (47.4% vs. 65.2%; P = 0.046) and MβL-negative-CR-E. coli (16.2% vs. 63.8%; P < 0.001) but not for MβL-negative-CR-C. freundii complex species (40% vs. 62%; P = 0.153). Amongst the PNIC-AmpC MβL-negative CRE isolates, resistance rates to ceftazidime-avibactam worsened. Caution should be taken when empirically prescribing ceftazidime-avibactam for infections caused by PNIC-AmpC-CRE before susceptibility data are available.
Keywords	Citrobacter freundii ; Enterobacter cloacae ; Escherichia coli ; Klebsiella aerogenes ; Providencia ; Serratia ; leadership ; minimum inhibitory concentration ; monitoring ; polymerase chain reaction
Language	English
Dates of publication	2022-0612
Publishing place	Elsevier Ltd
Document type	Article
Note	Pre-press version
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2022.106617
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito